All In Biotech

NDA 212726 · Genentech INC

Rozlytrek

Entrectinib · Oral

Breakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Aug 15, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

38

6 Phase 3, 12 recruiting

FAERS reports

1,691

1,103 serious, 275 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 15, 2019 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • ROZLYTREK · ENTRECTINIB 100MG · CAPSULE, ORAL · Prescription · TE TBD
  • ROZLYTREK · ENTRECTINIB 200MG · CAPSULE, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Entrectinib" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use173
  • dizziness157
  • death135
  • disease progression119
  • taste disorder74
  • no adverse event72
  • drug ineffective69
  • constipation68
  • blood creatinine increased66
  • fatigue64
  • diarrhoea63
  • renal impairment62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20181
201932
2020125
2021233
2022288
2023263
2024467
2025172
2026109

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rozlytrek (Entrectinib)

2024 spending

$19.1M

Beneficiaries

239

1,135 claims

Per beneficiary

$79,818

$219.73 per unit

View as table
YearSpending
2020$5,000,980
2021$9,829,447
2022$12,257,995
2023$15,596,859
2024$19,076,487

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.